TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain MetastasesRachel A. Freedman, Nancy U. Lin, Rebecca Gelman et al.|Journal of Clinical Oncology|2019Cited by 341
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer StudyRoisín M. Connolly, Vered Stearns, Antonio C. Wolff et al.|Clinical Cancer Research|2016Cited by 160
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarkerErica L. Mayer, Eric P. Winer, Vandana G. Abramson et al.|Annals of Oncology|2020Cited by 81
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancerCarey K. Anders, Jonathan S. Serody, Mark G. Woodcock et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 28